Bristol-Myers Squibb is trading 6.17% higher at $62.77, with no verified company-specific catalyst identified for the October 12 pre-market rise.
- Coverage of the BioNTech partnership refers to a deal announced in 2025, not overnight.
- Healthcare is up 1.58% pre-market, supported mainly by managed-care stocks, but that move does not clearly explain Bristol-Myers Squibb’s larger gain.
- No pre-market volume details were available.